- Free from Publisher GG Schwartz, AG Olsson, M Szarek, WJ … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—A total of 38% of patients (n = 1,161) met criteria for metabolic
syndrome as defined in this study and had a 19% incidence of a primary end point
event (death, nonfatal myocardial infarction, cardiac arrest, or recurrent ... Cited by 28 - Related articles - BL Direct - All 5 versions
T Celik, H Turhan, H Kursaklioglu, A Iyisoy, … - Coronary artery disease, 2006 - journals.lww.com Aims Metabolic syndrome with its associated cardiovascular risk factors and
prothrombotic, procoagulant and proinflammatory properties and its detrimental
effects on coronary microcirculation may play a role in the occurrence of ... Cited by 10 - Related articles - BL Direct - All 5 versions
- Free from Publisher K Pyörälä, CM Ballantyne, B Gumbiner, MW … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Over the 5.4-year median follow-up period, simvastatin produced
similar changes in serum lipid levels in 893 patients with the metabolic
syndrome and in 3,040 patients without the metabolic syndrome. The relative ... Cited by 80 - Related articles - BL Direct - All 8 versions
LC Clavijo, TL Pinto, PK Kuchulakanti, R … - Cardiovascular Revascularization Medicine, 2006 - Elsevier Metabolic syndrome (MS), the combination of hypertension, obesity, dyslipidemia,
and insulin resistance, is a precursor of diabetes mellitus (DM) and highly
prevalent among patients with acute myocardial infarction (AMI). Diabetes ... Cited by 30 - Related articles - All 9 versions
[CITATION] Lipoprotein changes and reduction in the incidence of major coronary heart disease events …
HH Chen, CJ Wu, YC Chen, CS Tsai, FJ Lin, … - Coronary artery disease, 2006 - journals.lww.com Objective: People with either end-stage renal disease or metabolic syndrome (MS)
are at increased risk for developing coronary artery disease. The impact of MS
on coronary artery disease in end-stage renal disease patients, however, ... Cited by 5 - Related articles - BL Direct - All 5 versions
- ►librapharm.co.uk [PDF] HJ Milionis, E Rizos, M Kostapanos, TD … - Current Medical Research and Opinion®, 2006 - informahealthcare.com Objectives: In a 24-week, open-label, randomized, parallel-group study, we
compared the efficacy and metabolic effects, beyond low density lipoprotein
cholesterol (LDL-C)-lowering, of atorvastatin (ATV) and rosuvastatin (RSV) ... Cited by 20 - Related articles - BL Direct - All 9 versions
HM Colhoun, DJ Betteridge, PN Durrington, … - Diabetologia, 2005 - Springer Abstract Aims/hypothesis: The aim of this study was to determine the pattern of
the effect of the 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor
atorva- statin on cardiovascular events in patients with type 2 diabetes ... Cited by 21 - Related articles - BL Direct - All 3 versions
- ►oxfordjournals.org S Ahmed, CP Cannon, SA Murphy, E … - European heart journal, 2006 - Eur Soc Cardiology Methods and results We explored this question in data from the Pravastatin or
Atorvastatin Evaluation and Infection Therapy (PROVE IT) TIMI 22 trial, which
tested standard (pravastatin 40 mg) vs. intensive (atorvastatin 80 mg) ... Cited by 23 - Related articles - BL Direct - All 6 versions
